The use of dabigatran in patients with mechanical heart valves compared with patients receiving warfarin was associated with increased rates of thromboembolic and bleeding complications, thus demonstrating no benefit and an excess risk.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content